Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 25,167

Document Document Title
WO/2021/069184A1
The present invention relates to a compound of formula (I), to the use thereof in electronic devices, to methods for producing said compound, and to electronic devices containing the compound.  
WO/2021/067324A1
Disclosed herein are novel uses of ADMDP stereoisomers or their derivatives for the manufacture of a medicament for treating Pompe disease. Accordingly, the present disclosure provides a method of treating Pompe disease in a subject. The...  
WO/2021/065483A1
A purification method in which an organic solvent, which has a boiling point exceeding 100°C at 1 atmosphere, is purified by being separated from a mixed solution of the organic solvent and water comprises: a step for passing the mixed ...  
WO/2021/063967A1
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...  
WO/2021/056647A1
The present application belongs to the technical fields of green catalysis and related chemistry, and discloses a catalyst for anti-Markovnikov hydroamination, a preparation method therefor and a use thereof. The catalyst consists of ato...  
WO/2021/058754A1
The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropi...  
WO/2021/058002A1
Disclosed by the present application is a crystalline form of a capsid protein assembly inhibitor containing an N hetero five-membered ring; specifically disclosed is the crystalline form of the compound of formula I; also comprised is a...  
WO/2021/061701A1
The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic...  
WO/2021/060517A1
The present invention provides a novel method for producing a derivative of an organic substance that contains one or more groups selected from the group consisting of a sulfanyl group, a selanyl group and a sulfino group. A method for p...  
WO/2021/058024A1
Provided are a class of heterospirocyclic compound which act as a lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in the preparation of a drug for treating diseases associated with LSD1. The heterospirocyclic compounds ...  
WO/2021/058001A1
Disclosed are a crystal form of a five-membered N heterocyclic compound, particularly, a crystal from of a compound as represented by formula I, and an application of the crystal form in preparation of a medication for preventing or trea...  
WO/2021/056850A1
Provided are an eutectic crystal formed by apixaban and a carboxylic acid, and a preparation method therefor. The eutectic crystal comprises an apixaban/malonic acid eutectic crystal, an apixaban/D‐malate eutectic crystal, an apixaban/...  
WO/2021/062168A1
Small molecules compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeuti...  
WO/2021/058021A1
A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug co...  
WO/2021/055630A1
The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical...  
WO/2021/055894A1
Methods of analyzing a drug polypeptide conjugate using tandem mass spectrometry involving dual tandem mass tags (TMTs) are described. Provided herein is an integrated method using TMTs to obtain three analytical measurements, termed "tr...  
WO/2021/047528A1
The present invention relates to the technical field of medicine, and disclosed are maleate of a nicotinyl alcohol ether derivative, a crystal form thereof, and an application thereof, i.e., (S)-N-(2-(pyridine-3-methoxy)-4-(2-bromo-3-phe...  
WO/2021/045153A1
Provided is a method for producing gamma-butyrolactone, said method including a reaction step in which a raw material composed of one or both of 2-hydroxytetrahydrofuran and 4-hydroxybutyraldehyde and a catalyst containing copper and an ...  
WO/2021/046286A1
A compound of Formula (I) below, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof: (I), in which Ra, Rb, Rc, Rd, X1, X2, R1-R4, W, Z, and L are defined as in the SUMMARY section. Further disclosed are a me...  
WO/2021/010681A3
The present invention provides a method for preparing a (3R,5R)-7-(2-(4-flurophenyl)-5-isopropyl-3-phenyl-4-((4-hydr oxymethylphenylamino)carbonyl)-pyrrole-1-yl)-3,5-dihydroxy heptanoic acid hemicalcium salt. The preparation method of th...  
WO/2021/046290A1
A pharmaceutical composition for topical wound treatment comprising one or more nitrogenous heterocyclic compound of 5 or 6 atoms with imide group; one or more deoxyribonuclease enzyme with activity pH between 4.5 and 6.5; and one or mor...  
WO/2021/041320A1
Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.  
WO/2021/038490A1
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3 ...  
WO/2021/030554A1
The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.  
WO/2021/027813A1
The present invention relates to a method for preparing asenapine. Specifically, the present invention relates to a method for preparing a pharmaceutically acceptable asenapine free base and a crystal form thereof, as well as a method fo...  
WO/2021/026047A1
The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or p...  
WO/2021/026257A1
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.  
WO/2021/026179A1
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...  
WO/2021/026465A1
Described herein are Janus kinase (JAK) inhibitors and methods of utilizing JAK inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.  
WO/2021/023818A1
The present invention relates to the field of flavor. More particularly, it concerns a precursor compound of formula (I) releasing 2-acetyl- 1-pyrroline and and a method to release 2-acetyl- 1-pyrroline from the precursor compound of for...  
WO/2021/021629A1
The invention is directed towards compounds (e.g., Formulae (I)-(IX)), their mechanism of action, processes to prepare the compounds, methods of activating quorum sensing signaling activity, and methods of treating diseases and disorders...  
WO/2021/020429A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.  
WO/2021/017904A1
Provided are fluorescent nanoparticles and their conjugates and methods of using the same for in vivo and in vitro diagnostics and other applications. In some embodiments, provided are fluorescent nanoparticles with high solid-state abso...  
WO/2021/007661A1
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...  
WO/2021/010681A2
The present invention provides a method for preparing a (3R,5R)-7-(2-(4-flurophenyl)-5-isopropyl-3-phenyl-4-((4-hydr oxymethylphenylamino)carbonyl)-pyrrole-1-yl)-3,5-dihydroxy heptanoic acid hemicalcium salt. The preparation method of th...  
WO/2021/007663A1
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...  
WO/2021/004401A1
The present invention relates to a crystal form of a key intermediate of a BTK kinase inhibitor and a preparation method therefor, and belongs to the technical field of medicines. The crystal form is a (R)-1-(1-(tert-butyloxyl)pyrrolidin...  
WO/2021/006598A1
The present invention relates to a method for purifying a waste N-methyl-2-pyrrolidone (hereinafter referred to as NMP) mixture solution and, more specifically, to a method for purifying a waster NMP mixture solution by using a base. Acc...  
WO/2020/264490A1
The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or ly...  
WO/2020/259471A1
Provided herein are oseltamivir analogs useful for the treatment and prevention of viral infections, pharmaceutical compositions comprising the same and methods preparation and use thereof.  
WO/2020/106642A8
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.  
WO/2020/258510A1
Provided by the present invention is a small molecule fluorescent agent. The structure of the small molecule fluorescent agent is represented by formula I. Further provided by the present invention is a method for preparing the small mol...  
WO/2020/262455A1
The present invention provides a means for increasing the solubility of even a poorly soluble amino acid without changing to an expensive peptide and also without changing the pH, and is characterized in that at least two kinds of amino ...  
WO/2020/262603A1
The purpose of the present invention is to provide a drug for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, the drug containing, as an active ingredient, a compound having an antagonistic...  
WO/2020/262648A1
The present invention provides a compound that has an excellent pest-controlling effect and that is represented by formula (I) [in the formula, L represents an oxygen atom or CH2, E represents a C2-C10 chain hydrocarbon group or the like...  
WO/2020/258709A1
The present invention relates to a synthesis method for ZP-1609, comprising the steps of: 1) selectively reacting to completion, 4-amino-L-proline tert-butyl ester with N-hydroxysuccinimide benzoate to obtain an intermediate product; 2) ...  
WO/2020/260526A1
The present invention relates to a new class of tertiary amine derivatives of formula (I) and their uses for treating viral infections, particularly viral respiratory infections. The present invention further relates to pharmaceutical co...  
WO/2020/261160A1
Methods for providing a carboxamide compound and intermediates used in the preparation of the carboxamide compound are provided. The methods include reacting 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylh exanenitrile benzo...  
WO/2020/264499A1
The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligas...  
WO/2020/254558A1
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...  

Matches 1 - 50 out of 25,167